Body Composition Analysis in Patients Undergoing Chemoembolization

Body Composition Analysis by Bioelectrical Impedance Vector Analysis in Patients With Hepatocellular Carcinoma Undergoing Chemoembolization.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01777698

Enrollment

Registered

2013-01-29

Start date

2012-04-30

Completion date

2016-03-31

Last updated

2016-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

body composition, hepatocellular carcinoma, chemoembolization

Brief summary

Hepatocellular carcinoma represents 80-90% of primary hepatic malignant tumors. 80% of patients with hepatocellular carcinoma are associated with cirrhosis. Chemoembolization is a process in which a chemotherapeutic agent is deposited directly into the hepatic tumor where the principal artery is embolized. Bioelectrical impedance bases its evaluation in a model where the body is conformed by two different compartments: fat mass and fat free mass. Bioelectrical impedance is complemented by vectorial analysis, which is independent to the state of hydration and is helpful to monitor any changes in corporal composition. It can be used as a control for the interpretation of the bioelectrical impedance.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients with hepato-renal disease * Patients with hepatocellular carcinoma that are put down to radiofrequency ablation * Patients with depression or any psiquiatric disease. * Patients that don't agree to participate in the project.

Exclusion criteria

* Patients with hepatocellular carcinoma that are put down to radiofrequency ablation * Patients with depression or any psiquiatric disease. * Patients that don't agree to participate in the project.

Design outcomes

Primary

Measure	Time frame	Description
Changes in body composition	1 hour before treatment, 2 weeks after treatment, and 1 month after treatment	To evaluate any changes in corporal composition in patients undergoing chemoembolization.

Countries

Mexico

Outcome results